Investigational drug · Phase 2
CD38
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
245
Any phase or sponsor naming "CD38"
First trial start
2025
Jul 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CD38", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CD38" as an intervention, largest first.
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for TransplantPivotal-lookingRecruiting
European Myeloma Network B.V.Research network
NCT06932562 · 1,000 participants (planned) · Start Dec 23, 2025 · Primary completion Dec 2036
Drug: Linvoseltamab; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Adelaide, Australia; Box Hill, Australia; Canberra, Australia · 59 sites in all
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomidePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06208150 · 838 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Talquetamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Clovis, California; Santa Monica, California; New Haven, Connecticut · 242 sites in all
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07518186 · 700 participants (planned) · Start May 31, 2026 · Primary completion Apr 29, 2029
Drug: JNJ-79635322; Teclistamab · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Springdale, Arkansas · 173 sites in all
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05572515 · 614 participants · Start Mar 29, 2023 · Primary completion Oct 13, 2025
Drug: Teclistamab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Anchorage, Alaska; Gilbert, Arizona; Berkeley, California · 211 sites in all
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Canadian Cancer Trials GroupResearch network
NCT06182774 · 570 participants (planned) · Start Apr 10, 2024 · Primary completion Jan 31, 2032
Drug: Daratumumab; Lenalidomide and 2 more · For: Multiple Myeloma
Sites: Edmonton, Canada; Kelowna, Canada; Vancouver, Canada · 31 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04634552 · 510 participants (planned) · Start Feb 1, 2021 · Primary completion Jun 30, 2027
Drug: Talquetamab · For: Hematological Malignancies
Sites: Birmingham, Alabama; Little Rock, Arkansas; Duarte, California · 78 sites in all
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05561387 · 510 participants (planned) · Start Oct 12, 2023 · Primary completion May 30, 2031
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Fort Smith, Arkansas · 397 sites in all
- Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04246047 · 494 participants · Start May 7, 2020 · Primary completion Oct 2, 2023
Drug: Belantamab mafodotin; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Yuma, Arizona; Mission, Kansas; Denver, North Carolina · 143 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical Trial of Open-Label Mezagitamab in IgAN: Final 96-Week Results.
Barratt J, Kim DK, Park I, et al. · Kidney Int Rep 2027
- Immunophenotyping of Human B Lymphocytes from Peripheral Blood Mononuclear Cells.
Lopez-Ocasio M, Lin WC, Hockman SC, et al. · Methods Mol Biol 2027
- TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectives.
Bhat AA, Fuloria S, Thapa R, et al. · Clin Chim Acta 2027
- Monoclonal gammopathy of clinical significance: the pathogenic paraprotein and a precision medicine roadmap.
Soleimani Samarkhazan H, Bahmani F, Rayati M, et al. · Hematology 2026
- Daratumumab in immune-mediated thrombotic thrombocytopenic purpura: emerging evidence for plasma cell-targeted therapy.
Mohammed Saleh MF, Alzaidy N, Nassani M, et al. · Hematology 2026
- Exploring the causal links among immune cell characteristics and prostatitis: a bidirectional two-sample Mendelian randomization study.
Wang Y, Xue C, Xu Z, et al. · Aging Male 2026
Also in development for Relapsed or Refractory Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- QLS32015Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Relapsed or Refractory Multiple Myeloma
- QLS4131Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma
- MBS314Phase 22 trials
Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma
- AZD4045Phase 21 trial
AstraZeneca · Relapsed or Refractory Multiple Myeloma
- F182112Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.